Friday, 13 Dec 2019

You are here

Diffuse Alveolar Hemorrhage in Lupus Reviewed

Diffuse alveolar hemorrhage (DAH) is a rare but catastrophic complication of systemic lupus erythematosus. Presentations are usually acute and the potential for significant morbidity and mortality risk mandates early diagnosis and aggressive interventions.

Kazzaz and colleagues identified 22 cases of DAH in a cohort of approximately 1000 lupus patients, and compared them to 66 controls from the same cohort. More then half (59%) were diagnosed with DAH within five years of their lupus diagnosis.

Several features were more common in patients with DAH: thrombocytopenia, cardiac valve disease, low C3, low C4, leukopenia, neuropsychiatric features, hemolysis, arterial thrombosis, lupus anticoagulant, and secondary APS. Only a history of thrombocytopenia and low C3 remained independent risk factors on multivate analyses. DAH is not a hemorrhagic condition as only 2 patients had platelet counts <50000/µL at the time of DAH.

All patients were treated with immunosuppressive therapy, including combinations of corticosteroids, plasmapheresis, cyclophosphamide, rituximab and mycophenolate mofetil. Although all 22 patients survived their initial DAH, their long-term survival, including death, was significantly worse than controls. 

Another recent study by Ednalino and coworkers reported a systematic review to assess outcomes and the effectiveness of different therapies for DAH. They identified 140 SLE patients and found survival to be 61% from the 174 DAH episodes reported. Survival trends appear to have increased from 25% in the 1980s to 67% in the current decade. (Citation source:

Treatments employed included corticosteroids (nearly all) and cyclophosphamide (in 55%). Plasmapheresis (in 31%) did not appear to be associated with survival. There are no randomized trials and the authors stressed that these results need to be interpreted with caution.

Nevertheless, diffuse alveolar hemorrhage in SLE still carries a high risk of mortality and the need for immediate aggressive therapy is great. They believe that Increased use of cyclophosphamide may be associated with better survival.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CRP in SSc: Identifying a Severe Phenotype

Patients with systemic sclerosis (SSc) who have persistent inflammation -- characterized by consistently elevated levels of C-reactive protein (CRP) -- have more severe disease and worse outcomes, a retrospective study confirmed.

Steroids Use in Lupus Linked to Damage Accural

A report from Lancet Rheumatology shows that glucocorticoid use contributes to damage accrual in systemic lupus erythematosus (SLE) independent of disease activity.

The authors undertook this study to evaluate the effects of steroid use in SLE, as it often confounds analyses of activity and damage.

Rheumatic Immune-Related Adverse Events: Not Just Another IrAE

Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.